<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41844">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01880424</url>
  </required_header>
  <id_info>
    <org_study_id>ICP-103-307</org_study_id>
    <nct_id>NCT01880424</nct_id>
  </id_info>
  <brief_title>A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</brief_title>
  <acronym>D5630C00001</acronym>
  <official_title>A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Australia: Therapeutic Goods Administration (TGA)</authority>
    <authority>New Zealand: Ministry of Health, Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is an international, multicenter, randomized, double-blind,
      placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo.
      Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be
      randomized at up to 60 trial centers in China, Australia, and New Zealand.

      The trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12
      weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment
      Period, patients meeting the entry criteria for this trial will be randomized to one of two
      double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Abdominal Pain/Abdominal Discomfort Weekly Responder rate</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 12-week Abdominal Pain/Abdominal Discomfort Responder is a patient who meets the Abdominal Pain/Abdominal Discomfort Weekly Responder criteria for at least 6 out of the first 12 weeks of the Treatment Period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irritable Bowel Syndrome (IBS) Degree of Relief Responder rate</measure>
    <time_frame>12weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 12-week IBS Degree of Relief Responder is a patient who meets the IBS Degree of Relief Weekly Responder criteria for at least 6 out of the 12 weeks of the Treatment Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Complete Spontaneous Bowel Movement Frequency Rate</measure>
    <time_frame>12weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Spontaneous Bowel Movement Frequency Rate</measure>
    <time_frame>12weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Stool Consistency</measure>
    <time_frame>12weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Severity of Straining</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Abdominal Bloating</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Abdominal Pain</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 12-week Abdominal Discomfort</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
  <arm_group>
    <arm_group_label>controlled arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching Placebo Capsules, Oral, once daily</description>
    <arm_group_label>controlled arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaclotide</intervention_name>
    <description>Linaclotide 290 ug Capsules, Oral, once daily</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has signed an Informed Consent Form(ICF).

          2. Patient Must not be pregnant or breastfeeding and agree to use birth control

          3. Patient meets the colonoscopy requirements defined by the American
             Gastroenterological Association guidelines and no clinically-significant laboratory
             or physical examination findings;

          4. Patient meets protocol-defined criteria for Irritable Bowel Syndrome with
             Constipation(IBS-C), including stool frequency, straining, stool consistency,
             abdominal pain, and abdominal discomfort criteria

          5. Patient meets protocol-defined eDiary completion Compliance and agrees to refrain
             from making any new, major life-style changes that may affect IBS-C symptoms

        Exclusion Criteria:

          1. Recent history of mushy or watery stools

          2. Various medical conditions, medical histories, or family medical histories that would
             not make the patient a good candidate for the study

          3. Patient currently has both unexplained and clinically significant alarm symptoms or
             systemic signs of infection or colitis.

          4. Surgery to the gastrointestinal tract

          5. Usage of prohibited medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunsheng Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese People's Liberation Army General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shutian Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhaoshen Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital Affiliated to Second Military Mecical University of Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weifen Xie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changzheng Hospital Affiliated to Second Military Mecical University of Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaozong Yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youqing Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongfeng Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Affiliated Hospital of Third Military Mecical University of Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Minhu Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanqing Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaozhong Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Shenyang Military Region of Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youlin Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rongquan Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Third Military Mecical University of Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaohua Hou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Union Hospital of Tongji Medical College of Huazhong University of Science &amp; Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liangping Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuang Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chengwei Tang</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianlin Ren</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital Affiliated to Xiamen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xizhong Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital Affiliated to Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yulan Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongmei Qian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital Affiliated to Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huahong Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lennie Wu, Master</last_name>
    <phone>86-2038183761</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Callaghan</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Five Dock</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malvern</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maroubra</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harerbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xiamen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
